glp-1 food industry news today Slideshow: friendly innovations on the upswing The Impact of GLP-1 on

Notably, based on the results from part 1 of the ESSENCE trial, on 15 August 2025, the FDA approved semaglutide 2.4 mg for the treatment of adults with MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)

GLP-1s lead to a decrease in the production of triglycerides and glucose, and an increase in glucose uptake, which ultimately may improve steatohepatitis, decrease fibrosis progression and reduce the risk of MASH complications

At the same time, it requires clinicians to balance: -evidence-based practice -clinical intuition -patient-specific context The most effective care often comes from the ability to hold multiple possibilities at once while continuing to move treatment forward

The oral segment is expected to witness a faster growth during the forecast period